Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Progeria medical therapy
Introduction
Overview
Overview
There is no treatment for Hutchinson-Gilford progeria syndrome (HGPS); the mainstay of therapy is supportive care. But the good news is that there are new investigational therapies for Hutchinson-Gilford progeria syndrome (HGPS) patients which include lonafarnib and everolimus.
Medical Therapy
Medical Therapy
- New investigational therapies for Hutchinson-Gilford progeria syndrome (HGPS) patients include the following:[1]
- Farnesyltransferase inhibitor (FTI)- Lonafarnib
- mTOR inhibitor- Everolimus
Lonafarnib
- Lonafarnib is a farnesyltransferase inhibitor (FTI).[2]
- Mechanism action of lonafarnib is it may inhibit the formation of the truncated lamin A protein which is called progerin.
- Lonafarnib also inhibit anchoring of the protein lamin A to the inner surface of the nuclear membrane, thus significantly improving disease results in Hutchinson-Gilford progeria syndrome (HGPS) patients.
- Lonafarnibis administered orally twice a day.
- Using lonafarnib on patients with Hutchinson-Gilford progeria syndrome (HGPS) shows good improvements on the following:[3][4]
- Lonafarnib improves weight gain
- Lonafarnib improves vascular distensibility
- Lonafarnib improves vascular echodensity
- Lonafarnib improves skeletal rigidity
- Lonafarnib improves vascular stiffness
- Lonafarnib improves bone rigidity
- Lonafarnib improves neurosensory hearing
- Lonafarnib reduces the prevalence of stroke and TIA
- Lonafarnib improves headaches
- Lonafarnib improves life span in patients with HGPS[5]
Everolimus
- Everolimus is a rapamycin-like drug which is a mTOR inhibitor which improves cellular autophagy.[6][7][8]
- Everolimus is a oral medication and should be given once daily on daily basis.
- Everolimus mechanism of action is it improves cellular phenotypes in HGPS fibroblasts via increased autophagy(self-eating)
References
References
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). “GeneReviews®”. PMID 20301300.
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). “GeneReviews®”. PMID 20301300.
- ↑ Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M; et al. (2012). “Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome”. Proc Natl Acad Sci U S A. 109 (41): 16666–71. doi:10.1073/pnas.1202529109. PMC 3478615. PMID 23012407.
- ↑ Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM; et al. (2013). “Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment”. Neurology. 81 (5): 427–30. doi:10.1212/WNL.0b013e31829d85c0. PMC 3776537. PMID 23897869.
- ↑ Gordon LB, Massaro J, D’Agostino RB, Campbell SE, Brazier J, Brown WT; et al. (2014). “Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome”. Circulation. 130 (1): 27–34. doi:10.1161/CIRCULATIONAHA.113.008285. PMC 4082404. PMID 24795390.
- ↑ Cenni V, Capanni C, Columbaro M, Ortolani M, D’Apice MR, Novelli G; et al. (2011). “Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria”. Eur J Histochem. 55 (4): e36. doi:10.4081/ejh.2011.e36. PMC 3284238. PMID 22297442.
- ↑ Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR; et al. (2011). “Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts”. J Clin Invest. 121 (7): 2833–44. doi:10.1172/JCI43578. PMC 3223819. PMID 21670498.
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). “GeneReviews®”. PMID 20301300.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]